Last updated on January 2020

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)


Brief description of study

Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced breast cancer (ABC)

Detailed Study Description

Pre- and post-menopausal women age 18 years with HR-positive and HER2-negative with ABC that had previously received first-line endocrine therapy in combination with palbociclib and had achieved clinical benefit during palbociclib-based treatment. Patients relapsing on a palbociclib-based regimen in the adjuvant setting are also eligible. Patients are not eligible if they are candidates for a local treatment with a curative intention. Evidence of either measurable and biopsiable metastatic disease (as for Response Evaluation Criteria In Solid Tumors (RECIST v.1.1)) or non-measurable disease with bone lesion is required. Pre-menopausal women must be under treatment with luteinizing hormone-releasing hormone (LHRH) analogues.

Clinical Study Identifier: NCT03809988

Find a site near you

Start Over

ICO Badalona

Badalona, Spain
  Connect »

Chd-Vendee

La Roche-sur-Yon, France
  Connect »

Barts Cancer Institute

London, United Kingdom
  Connect »

Kent Oncology Department

Maidstone, United Kingdom
  Connect »